Key Facts Surrounding This News Item
- PRNB had returned 0.00% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period.
More Info About Principia Biopharma Inc. (PRNB)
Principia Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has collaboration agreements with Genzyme Corporation and AbbVie Biotechnology Limited. Principia Biopharma Inc. was founded in 2008 and is based in South San Francisco, California. View our full PRNB ticker page with ratings, news, and more.